Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

581 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.
Gauci ML, Giustiniani J, Lepelletier C, Garbar C, Thonnart N, Dumaz N, Foussat A, Lebbé C, Bensussan A, Marie-Cardine A. Gauci ML, et al. Among authors: lebbe c. Cancer Immunol Immunother. 2022 Nov;71(11):2731-2742. doi: 10.1007/s00262-022-03199-0. Epub 2022 Apr 15. Cancer Immunol Immunother. 2022. PMID: 35428910 Free PMC article.
Driver KIT mutations in melanoma cluster in four hotspots.
Dumaz N, André J, Sadoux A, Laugier F, Podgorniak MP, Mourah S, Lebbé C. Dumaz N, et al. Among authors: lebbe c. Melanoma Res. 2015 Feb;25(1):88-90. doi: 10.1097/CMR.0000000000000116. Melanoma Res. 2015. PMID: 25304235
PARKIN Inactivation Links Parkinson's Disease to Melanoma.
Hu HH, Kannengiesser C, Lesage S, André J, Mourah S, Michel L, Descamps V, Basset-Seguin N, Bagot M, Bensussan A, Lebbé C, Deschamps L, Saiag P, Leccia MT, Bressac-de-Paillerets B, Tsalamlal A, Kumar R, Klebe S, Grandchamp B, Andrieu-Abadie N, Thomas L, Brice A, Dumaz N, Soufir N. Hu HH, et al. Among authors: lebbe c. J Natl Cancer Inst. 2015 Dec 17;108(3). doi: 10.1093/jnci/djv340. Print 2016 Mar. J Natl Cancer Inst. 2015. PMID: 26683220
Validation of a preclinical model for assessment of drug efficacy in melanoma.
Delyon J, Varna M, Feugeas JP, Sadoux A, Yahiaoui S, Podgorniak MP, Leclert G, Dorval SM, Dumaz N, Soulie J, Janin A, Mourah S, Lebbé C. Delyon J, et al. Among authors: lebbe c. Oncotarget. 2016 Mar 15;7(11):13069-81. doi: 10.18632/oncotarget.7541. Oncotarget. 2016. PMID: 26909610 Free PMC article.
PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.
Delyon J, Servy A, Laugier F, André J, Ortonne N, Battistella M, Mourah S, Bensussan A, Lebbé C, Dumaz N. Delyon J, et al. Among authors: lebbe c. Oncogene. 2017 Jun 8;36(23):3252-3262. doi: 10.1038/onc.2016.469. Epub 2017 Jan 16. Oncogene. 2017. PMID: 28092671
Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
Gauci ML, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, Da Meda L, Madelaine-Chambrin I, Bagot M, Basset-Seguin N, Pages C, Mourah S, Boudou P, Lebbé C, Gautier JF. Gauci ML, et al. Among authors: lebbe c. Cancer Immunol Immunother. 2017 Nov;66(11):1399-1410. doi: 10.1007/s00262-017-2033-8. Epub 2017 Jun 20. Cancer Immunol Immunother. 2017. PMID: 28634815 Free PMC article. Review.
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.
Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C; GCC (French Group of Skin Cancer). Delyon J, et al. Among authors: lebbe c. J Invest Dermatol. 2018 Jan;138(1):58-67. doi: 10.1016/j.jid.2017.07.839. Epub 2017 Aug 24. J Invest Dermatol. 2018. PMID: 28843487 Free article. Clinical Trial.
581 results